TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

Court Ruling Ends Edwards Lifesciences $1.2 Billion Plan To Acquire JenaValve

Benzinga Logo Benzinga By Vandana Singh
Court Ruling Ends Edwards Lifesciences $1.2 Billion Plan To Acquire JenaValve

A U.S. District Court granted the FTC's motion to block Edwards Lifesciences' $1.2 billion acquisition of JenaValve Technology, citing concerns that the deal would eliminate competition in the TAVR-AR device market and potentially harm innovation and patient access. Despite the setback, Edwards raised its 2026 adjusted EPS guidance to $2.90-$3.05 and continues advancing its own transcatheter aortic regurgitation valve.

Insights
BIVIW   positive

Company is advancing multiple late-stage clinical programs with promising drug candidates targeting significant medical conditions, showing strong safety data and potential for market expansion


EW   neutral

The company faced a significant setback with the blocked acquisition, which is negative. However, this was offset by raised 2026 EPS guidance and continued progress on its own SOJOURN transcatheter valve program, resulting in a neutral overall sentiment.